Riverview Trust Company’s AngioDynamics ANGO Stock Holding History

Riverview Trust Company’s Portfolio ANGO Stock Details ANGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-33	Closed	-$1K	–	274
2019 Q1	$1K	Buy	+33	New	+$716	﹤0.01%	426

Other funds holding ANGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TCM

Tributary Capital Management Omaha, Nebraska $1.22B AUM 44.12% 1-Year Est. Return

Riverview Trust Company's ANGO Position: Q2 2019 in Review

Riverview Trust Company sold out of AngioDynamics (ANGO) in Q2 2019, closing a stake of 33 shares — an estimated $1K sold.

Riverview Trust Company first reported a position in ANGO in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 167 funds tracked by Wall St. Rank hold ANGO as of Q2 2019.

Riverview Trust Company reported no remaining AngioDynamics position as of Q2 2019 after selling out during the quarter.
Riverview Trust Company sold 33 AngioDynamics shares in Q2 2019, an estimated $1K.
Riverview Trust Company first reported a position in AngioDynamics in Q1 2019 and held it in 1 quarter.
Riverview Trust Company's AngioDynamics position peaked at $1K in Q1 2019.
167 funds tracked by Wall St. Rank held AngioDynamics as of Q2 2019.

Based on Riverview Trust Company's 13F filing for Q2 2019, filed 12 Jul 2019.